Apolipoprotéine C-III (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Apolipoprotéine C-III" in French language version.

refsWebsite

Global rank French rank

4ahajournals.org

3,608^th place

659^th place

2ensembl.org

1,626^th place

2,018^th place

2nih.gov

4^th place

12^th place

2nejm.org

2,374^th place

298^th place

2jlr.org

low place

1jci.org

low place

3,702^nd place

1sciencemag.org

857^th place

208^th place

1jbc.org

4,455^th place

1,915^th place

1endojournals.org

low place

3,196^th place

1sciencedirect.com

149^th place

80^th place

ahajournals.org

endojournals.org

jcem.endojournals.org

Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G, Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity, J Clin Endocrinol Metab, 2004;89:3949–3955

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000110245 - Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000032081 - Ensembl, May 2017

jbc.org

Qin W, Sundaram M, Wang Y et al. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen, J Biol Chem, 2011;286:27769–27780

jci.org

Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T, Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia, J Clin Invest, 1995;96:2601–2605

jlr.org

McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS, Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III, J Lipid Res, 1992;33:995–1003
Huff MW, Fidge NH, Nestel PJ, Billington T, Watson B, Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects, J Lipid Res, 1981;22:1235–1246

nejm.org

The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Loss-of-function mutations in APOC3, triglycerides, and coronary disease, N Engl J Med, 2014;371:22-31
Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A, Loss-of-function mutations in APOC3 and risk of ischemic vascular disease, N Engl J Med, 2014;371:32-41

nih.gov

ncbi.nlm.nih.gov

« Publications PubMed pour l'Homme », sur National Center for Biotechnology Information, U.S. National Library of Medicine
« Publications PubMed pour la Souris », sur National Center for Biotechnology Information, U.S. National Library of Medicine

sciencedirect.com

Pechlaner R, Tsimikas S, Yin X et al. Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III, J Am Coll Cardiol, 2017;69:789–800

sciencemag.org

Pollin TI, Damcott CM, Shen H et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection, Science, 2008;322:1702–1705

Apolipoprotéine C-III (French Wikipedia)

ahajournals.org

circres.ahajournals.org

atvb.ahajournals.org

circ.ahajournals.org

endojournals.org

jcem.endojournals.org

ensembl.org

May2017.archive.ensembl.org

jbc.org

jci.org

jlr.org

nejm.org

nih.gov

ncbi.nlm.nih.gov

sciencedirect.com

sciencemag.org